Abstract
Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. Not much is known about the clearance capability with extracorporeal techniques of dabigatran. This review showcases the pharmacokinetics and a perusal of the current literature regarding cases that involved the clearance of the drug in patients with normal renal function and end-stage renal disease. Renal replacement therapy represents a therapeutic option to eliminate dabigatran and decreased the risk of bleeding in patients undergoing emergent surgical procedures on dabigatran.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e485-e488 |
| Journal | American journal of therapeutics |
| Volume | 23 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2016 |
Keywords
- bleeding
- dabigatran
- dialysis
- renal replacement therapy
- thrombin inhibitors
- toxicity
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Use of extracorporeal techniques in the removal of dabigatran'. Together they form a unique fingerprint.
Cite this
Muddana, N., Thuyanh, C., Nayer, A., Nashar, K., & Ortega, L. M. (2016). Use of extracorporeal techniques in the removal of dabigatran. American journal of therapeutics, 23(2), e485-e488. https://doi.org/10.1097/MJT.0000000000000082